CHRONIC HEPATITIS B

This study tests a new drug called bepirovirsen in about 857 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can achieve a functional cure, meaning the virus is suppressed and no longer detectable after stopping al…

This study tests whether adding a PD-1 antibody (sintilimab) and pegylated interferon to standard antiviral therapy can cure chronic hepatitis B. The goal is to eliminate the hepatitis B surface antigen (HBsAg) from the blood, which would mean the virus is no longer active. The s…

This study tests a new drug called bepirovirsen to see if it can cure chronic hepatitis B. About 981 adults who are already on standard antiviral therapy will receive either bepirovirsen or a placebo for 24 weeks, then stop all hepatitis B treatments to see if the virus stays sup…

This early-stage study tests a new therapeutic hepatitis B vaccine (AVX70371) in 16 healthy adults aged 18-40. The main goal is to check safety and side effects, and to see how the immune system responds. It is a first step toward possibly treating chronic hepatitis B.

This study tests a new drug called AHB-137 in 105 adults with chronic hepatitis B who have not been treated before. The goal is to see if the drug can lower the virus to undetectable levels and possibly achieve a functional cure, where the virus stays under control even after sto…

This study looks at whether a combination of natural herbs (Phyllanthus urinaria, Adenosma glutinosum, Eclipta prostrata) plus vitamin C and the drug tenofovir can help control hepatitis B over the long term. It includes adults with chronic or acute hepatitis B who have had the v…

This study tests whether the antiviral drug tenofovir can safely lower hepatitis B virus levels in children aged 2 to 12 with chronic infection. Participants receive either the drug or a placebo for 48 weeks. The goal is to see if the drug can control the virus and improve liver …

This study tests two experimental injections, HT-101 and HT-102, in 60 adults with chronic hepatitis B. The goal is to see if the combination can lower the virus to undetectable levels and keep it under control. Participants must already be on standard antiviral therapy. The tria…

This study tests whether empagliflozin, a diabetes drug, can prevent liver scarring (fibrosis) from getting worse in people with chronic hepatitis B. About 106 adults with moderate to severe liver scarring will take either the drug or a placebo daily for three years. The goal is …

This study tests an experimental injection called AHB-137 in 20 adults with chronic hepatitis B who are already taking standard antiviral pills. The goal is to see if the injection can help the body clear the virus and reduce markers of infection. Participants will receive the in…

This study planned to test a new drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if adding ARC-520 could lower a key virus marker (HBsAg) more effectively. However, the study was withdrawn before a…

This study looks at whether switching kidney or liver transplant patients with chronic hepatitis B to a newer drug called tenofovir alafenamide (TAF) is safe and effective. About 52 adults who have had a transplant and are on other hepatitis B medications will be switched to TAF.…

This study tests whether adding an experimental drug (AHB-137) to either a hepatitis B vaccine or an immune-boosting medicine (pegylated interferon) can help people with chronic hepatitis B stop their daily antiviral pills without the virus coming back. About 127 adults with HBeA…

This study tests an experimental injection called AHB-137 in adults with a type of chronic hepatitis B (HBeAg-negative) who are already on standard antiviral pills. The goal is to see if AHB-137 can clear the hepatitis B surface antigen (HBsAg) from the blood and keep the virus u…

This study tests two experimental injections (HT-101 and HT-102) in about 86 people with chronic hepatitis B. Participants also take standard antiviral pills. The main goals are to check safety and how the body processes the drugs. This is an early-phase trial, so it focuses on s…

This study tests a drug called TMF (Amibufenamide) in 200 adults with chronic hepatitis B who have normal liver enzyme (ALT) levels. The goal is to see if TMF can lower the amount of hepatitis B virus in the blood to undetectable levels after 48 weeks. Participants are randomly a…

This early-phase study tests a new injection called TVAX-008 in 20 adults with chronic hepatitis B who have very low virus levels or have lost the virus surface marker but not yet developed protective antibodies. The goal is to see if the injection can safely boost the body's imm…

This study tests whether adding an experimental drug (TQ-A3334) to standard antiviral pills can better control chronic hepatitis B. About 116 adults with long-term infection will receive either the drug or a placebo, plus their usual medication. The main goal is to see if the com…

This study tests a new oral medication, hepenofovir fumarate, for people with chronic hepatitis B. It involves 1444 adults aged 18-65 who have not been treated before or have stopped treatment. The goal is to find the best dose that controls the virus safely, compared to an exist…

This study tests whether a new drug called BW-20507, given together with pegylated interferon alfa, can help people with chronic hepatitis B stop their daily antiviral pills. About 209 adults aged 18 to 65 with stable hepatitis B will receive the combination. The main goal is to …

This study is for people with chronic hepatitis B who stopped their antiviral medication, then had a dangerous flare-up of the virus. It tests if switching to a newer drug called tenofovir alafenamide (TAF) is effective at getting the virus back under control. The goal is to see …

This study looks at 54 adults with chronic hepatitis B who have been on long-term antiviral medication. Researchers want to understand the immune system and virus changes that happen after stopping treatment, especially if a mild liver flare occurs. The goal is to gather informat…